Enteropathy-Associated T-Cell Lymphoma · line 2 · ICE (Ifosfamide + Carboplatin + Etoposide), 3 cycles
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-ICE |
| ID | IND-EATL-2L-ICE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-EATL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB. Brentuximab-vedotin monotherapy may be considered if CD30+ EATL (variable expression — rebiopsy if available). Outcomes overall poor; prioritize donor identification and clinical trial enrollment.
Used By
No reverse references found in the YAML corpus.